Who Will Lead the FDA?

Overview

The FDA is in a state of transition with new leadership candidates under review. The agency faces significant challenges, including regulatory scrutiny.

Background

The FDA plays a crucial role in regulating a significant portion of the U.S. economy, impacting public health through its oversight of drug approvals and safety. Recent turmoil within the agency has raised concerns about its ability to effectively manage these responsibilities.

Data Highlights

No numerical or trial data available in the source material.

Key Findings

• Matt Wilsey's efforts to develop a gene therapy for his daughter’s NGLY1 deficiency highlight the challenges faced by parents in the rare disease community.
• The FDA's current leadership transition includes finalists with diverse backgrounds.
• Professional football players are nearly four times more likely to die from neurodegenerative diseases compared to the general population, as reported in a study by Mass General Brigham.
• Concerns have been raised about the potential for the Department of Health and Human Services to compile an overly broad list of Covid vaccine injuries under Secretary Robert F. Kennedy Jr.
• Changes in federally funded research regulations may have lasting impacts on scientific integrity and funding.

Clinical Implications

Clinicians should remain informed about potential changes in approval processes.

Conclusion

The future leadership of the FDA is critical as it navigates complex challenges in drug regulation and public health.

Related Resources & Content

1. Associated Press Health, AP News, 2025 -- Rick Pazdur to replace George Tidmarsh at FDA drug center
2. the asco post, ASCO Post, 2025 -- Longtime FDA Innovator Appointed as Director of CDER
3. The ASCO Post, ASCO Post, 2016 -- Charting a New Course at the FDA
4. conexiant, Conexiant, 2025 -- Makary Resigns as FDA Commissioner Following Policy Disputes
5. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026, Diabetes Journals, 2026
6. Donanemab Appropriate Use Recommendations - PMC, PMC, 2025
7. Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel - PMC, PMC, 2025
8. conexiant — Makary Resigns as FDA Commissioner Following Policy Disputes
9. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026
10. Donanemab Appropriate Use Recommendations - PMC
11. Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel - PMC